<p>DUALITYBIO-B (09606.HK) announced its 2025 annual results, with revenue recorded at RMB 1.852 billion, a year-on-year decrease of 4.6%. The loss expanded from RMB 1.05 billion in the previous year to RMB 2.595 billion, with a loss per share of RMB 39.8. No final dividend will be distributed</p>

159849

159992

513700

<p>DUALITYBIO-B announced its 2025 annual performance, with revenue recorded at RMB 1.852 billion, a year-on-year decrease of 4.6%. Losses expanded from RMB 1.05 billion in the previous year to RMB 2.595 billion, with a loss per share of RMB 39.8. No final dividend will be distributed</p>

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

DUALITYBIO-B

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

"Performance" DUALITYBIO's annual loss expands to 2.595 billion RMB